CSF Aβ1-42 (marker for Aβ deposition), total tau protein (T-tau; marker for neuronal injury), and phosphorylated tau at threonine 181 (P-tau181; marker for NFT) are validated and integrated CSF biomarkers in the revised diagnostic criteria of AD [7, 12–14, 27]. Here, MAPT is linked to Alzheimer disease.